Pharmacological Treatment of Chronic Congestive Heart Failure

1. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). European Heart Journal, Volume 37, Issue 27, 14 July 2016, Pages 2129–2200, https://doi.org/10.1093/eurheartj/ehw128.10.1093/eurheartj/ehw12827206819 Search in Google Scholar

2. Поскурица М, Петровић Д. Застојна срчана инсуфицијенција код болесника са оштећеном функцијом бубрега. Srp Arh Celok Lek. 2014 Nov-Dec;142(11-12):747-755 DOI: 10.2298/SARH1412747P; UDC: 616.12-008.6; 616.61-78. Search in Google Scholar

3. Januzzi LJ, Jr., Mann LD. Clinical Assessment of Heart Failure. In. Douglas LM, Zipes DP, Libby P, Bonow RO, Braunwald E. Braunwald’s Heart Disease a Textbook of Cardiovascular Medicine, 10th ed., Elsevier-Saunders co. Philadelphia, 2015; Chapt 23: 473 – 483. ISBN: 978-1-4557-5134-1. Search in Google Scholar

4. Hanna BE. Practical Cardiovaskular Medicine, 2017; Willey Blackwell, Part 2.: 93-141; ICBN: 9781119233497. Search in Google Scholar

5. Felker MG, Ellison HD, Mullens W, Cox LZ, Testani. MJ. Diuretic Therapy for Patients With Heart Failure. J Am Coll Cardiol. 2020 Mar, 75 (10) 1178–1195. doi: 10.1016/j.jacc.2019.12.059.10.1016/j.jacc.2019.12.05932164892 Search in Google Scholar

6. Januzzi LJ, Mann LD. Clinical Assessment of Heart Failure. In. Douglas LM, Zipes DP, Libby P, Bonow RO, Braunwald E. Braunwald’s Heart Disease a Textbook of Cardiovascular Medicine, 10th ed., Elsevier-Saunders co. Philadelphia, 2015; Chapt 23: 473 – 483. ISBN: 978-1-4557-5134-1. Search in Google Scholar

7. Nadar KS, Shaikh MM. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev. 2019 Feb; 5(1): 50-56. doi: 10.15420/cfr.2018.27.210.15420/cfr.2018.27.2639606330847246 Search in Google Scholar

8. Poskurica M, Poskurica M, Stevanović Đ. Cardiorenal syndrome – have cardiologysts and nephrologists met half way. Cardionephrology and Hypertension Congress, Punta, Niš 2017; 2-16. ISBN: 978-86-7990-174-3. Search in Google Scholar

9. Chavey EW, Hogikyan VR, Harrison VR, Nicklas MJ. Heart Failure Due to Reduced Ejection Fraction: Medi cal Management.Am Fam Physician. 2017 Jan 1;95(1): 13-20. Search in Google Scholar

10. Mann LD. Management of Patients with Heart Failure with Reduced Ejection Fraction. In. Douglas LM, Zipes DP, Libby P, Bonow RO, Braunwald E. Braunwald’s Heart Disease a Textbook of Cardiovascular Medicine, 10th ed., Elsevier-Saunders co. Philadelphia, 2015; Chapt 25: 512 - 556. ISBN: 978-1-4557-5134-1. Search in Google Scholar

11. Clinical Statements and Guidelines - ACC/AHA/HFSA Focused Update. Circulation. Volume 136, Issue 6, 2017:136:e137–e161. Search in Google Scholar

12. Damman K, Harjola V‐P, Mebazaa A, Martens P et al. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology, European Journal of Heart Failure (2019); 21: 137–155; doi:10.1002/ejhf.136910.1002/ejhf.136930600580 Search in Google Scholar

13. Khan SM, Fonarow CG, Ahmed A, Greene JS et al. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure. A Meta-Analysis. Circulation: Heart Failure. 2017;10.10.1161/CIRCHEARTFAILURE.117.00395628790052 Search in Google Scholar

14. Tse S. Mazzola N. Ivabradine (Corlanor) for Heart Failure: The First Selective and Specific I_f Inhibitor. PT: 2015 Dec; 40(12): 810–814. PMID: 26681903 Search in Google Scholar

15. McMurray JV, Solomon DS, Inzucchi ES, Køber L, Kosiborod NM et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019; 381:1995-2008 DOI: 10.1056/NEJMoa 1911303. Search in Google Scholar

16. Poskurica M. Cardionephrology – present and future. Cardionephrology and Hypertension Congress, Punta, Niš 2019; 1-12. ISBN: 978-86-7990-197-2. Search in Google Scholar

17. Metra M, Dinatolo E, Dasseni N. The New Heart Failure Association Definition of Advanced Heart Failure. Card Fail Rev. 2019 Feb; 5(1): 5–8. doi: 10.15420/cfr. 2018.43.1; PMID: 30847238.10.15420/cfr Search in Google Scholar

18. Abou Ezzeddine FO. Who Has Advanced Heart Failure? Definition and Epidemiology. Congest Heart Fail. 2011 Jul-Aug;17(4); doi: 10.1111/j.1751-7133.2011.00246.x.10.1111/j.1751-7133.2011.00246.x385775921790965 Search in Google Scholar

19. Hoorn JE, Ellison HD. Diuretic Resistance. Am J Kidney Dis. Am J Kidney Dis. 2017 Jan; 69(1): 136-142; PMID: 27814935.10.1053/j.ajkd.2016.08.027518208727814935 Search in Google Scholar

20. Ravnan, LS, Ravnan CM, Prakash C. Diuretic Resistance and Strategies to Overcome Resistance in Patients With Congestive Heart Failure. Congestive Heart Failure, Vol 8; 80-85. https://doi.org/10.1111/j.1527-5299.2002.0758.x.10.1111/j.1527-5299.2002.0758.x11927781 Search in Google Scholar

21. Eric C. Siddall CE, Radjakrishnan J. Principles of Diuretic Management in Heart Failure. In. Ronco C, Bellomo R. Critical care nephrology, 3^rd Ed., Elsevier 2019; Chapt. 118: 721–726. ISBN: 978-0-323-44942-7.10.1016/B978-0-323-44942-7.00118-7 Search in Google Scholar

22. Tuttolomondo A, Pinto A, Parrinello G, Licata G. Intravenous High-Dose Furosemide and Hypertonic Saline Solutions for Refractory Heart Failure and Ascites. Seminars in Nephrology, Vol 31, No 6, November 2011, pp 513-522. doi:10.1016/j.semnephrol. 2011.09.006. Search in Google Scholar

23. Dasgupta K, Pichhadze SR, Khan N. Powerful diuretics: A common denominator in landmark hypertension and type 2 diabetes mellitus trials. JCH,2018; https://doi.org/10.1111/jch.1315110.1111/jch.13151803092129265730 Search in Google Scholar

24. Biolo A, Givertz MM. Colucci SW. Inotropic and Vasoactive Agents. In. David L. Brown: Cardiac Intensive Care. 3rd Ed. Pages 394-401.e3. ISBN 978-0-323-52993-8.10.1016/B978-0-323-52993-8.00037-0 Search in Google Scholar

25. Felker MG, Teerlink RJ. Diagnosis and Management of Acute Heart Failure. In. Douglas LM, Zipes DP, Libby P, Bonow RO, Braunwald E. Braunwald’s Heart Disease, a Textbook of Cardiovascular Medicine, 10th Ed., Elsevier-Saunders co. Philadelphia, 2015; Chapt 24: 484 – 512, ISBN: 978-1-4557-5134-1. Search in Google Scholar

26. Mehra RM. Heart Failure: Management In. Jameson, Fauci, Casper et al. Harrison’s Principles of Internal Medicine, 20ed. Chapt. 253:1769 – 1779. McGraw-Hill 2018; ISBN: 978-1-25-964404-7. Search in Google Scholar

27. Kasikcioglu AH, Cam N. A review of levosimendan in the treatment of heart failure. Vasc Health Risk Manag. 2006 Dec; 2(4): 389–400. PMID: 1732359310.2147/vhrm.2006.2.4.389199402317323593 Search in Google Scholar

28. Pashkovetsky E, Chhaya GA, Wilbert SW. Use of levosimendan in acute a nd advanced heart failure: short review on available real-world data.Ther Clin Risk Manag. 2019; 15: 765–772. doi: 10.2147/TCRM.S188761.10.2147/TCRM.S188761658871231354283 Search in Google Scholar

29. Edgardo Kaplinsky E, Mallarkey G. Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil. Drugs Context. 2018; 7: 212518; 2018 Apr 23. doi: 10.7573/dic.212518, PMID: 29707029.10.7573/dic.212518591609729707029 Search in Google Scholar